{
    "info": {
        "nct_id": "NCT03098550",
        "official_title": "Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined With Daratumumab in Participants With Advanced or Metastatic Solid Tumors",
        "inclusion_criteria": "For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com\n\n* Patients with metastatic or advanced solid tumors\n* Women with histologically or cytologically confirmed triple negative breast carcinoma\n* Participants with histologically or cytologically confirmed pancreatic adenocarcinoma\n* Participants with histologically or cytologically confirmed Non Small Cell Lung Cancer (NSCLC)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Active brain metastases or leptomeningeal metastases.\n* Any serious or uncontrolled medical disorder\n* Prior malignancy active within the previous 3 years\n\nOther protocol defined inclusion/exclusion criteria could apply",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with histologically or cytologically confirmed Non Small Cell Lung Cancer (NSCLC)",
            "criterions": [
                {
                    "exact_snippets": "histologically or cytologically confirmed Non Small Cell Lung Cancer (NSCLC)",
                    "criterion": "Non Small Cell Lung Cancer (NSCLC)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women with histologically or cytologically confirmed triple negative breast carcinoma",
            "criterions": [
                {
                    "exact_snippets": "Women",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                },
                {
                    "exact_snippets": "histologically or cytologically confirmed",
                    "criterion": "breast carcinoma diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "confirmation_method",
                            "expected_value": [
                                "histology",
                                "cytology"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "triple negative breast carcinoma",
                    "criterion": "breast carcinoma subtype",
                    "requirements": [
                        {
                            "requirement_type": "subtype",
                            "expected_value": "triple negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with metastatic or advanced solid tumors",
            "criterions": [
                {
                    "exact_snippets": "metastatic or advanced solid tumors",
                    "criterion": "solid tumors",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "metastatic",
                                "advanced"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with histologically or cytologically confirmed pancreatic adenocarcinoma",
            "criterions": [
                {
                    "exact_snippets": "histologically or cytologically confirmed pancreatic adenocarcinoma",
                    "criterion": "pancreatic adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis confirmation method",
                            "expected_value": [
                                "histological",
                                "cytological"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "Other protocol defined inclusion/exclusion criteria could apply",
            "criterions": [
                {
                    "exact_snippets": "Other protocol defined inclusion/exclusion criteria could apply",
                    "criterion": "other protocol defined inclusion/exclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any serious or uncontrolled medical disorder",
            "criterions": [
                {
                    "exact_snippets": "Any serious or uncontrolled medical disorder",
                    "criterion": "medical disorder",
                    "requirements": [
                        {
                            "requirement_type": "seriousness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior malignancy active within the previous 3 years",
            "criterions": [
                {
                    "exact_snippets": "Prior malignancy active within the previous 3 years",
                    "criterion": "prior malignancy",
                    "requirements": [
                        {
                            "requirement_type": "activity_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active brain metastases or leptomeningeal metastases.",
            "criterions": [
                {
                    "exact_snippets": "Active brain metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "leptomeningeal metastases",
                    "criterion": "leptomeningeal metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com",
            "criterions": []
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}